Open access
Open access
Powered by Google Translator Translator

Hematology (all articles)

Cohort Study | Incidence and impact of anticoagulation-associated abnormal menstrual bleeding after VTE

27 Jan, 2023 | 12:04h | UTC

Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism – Blood

Invited Commentary: The burden of heavy menstrual bleeding – Blood

 

Commentary on Twitter

 


Post-trial follow-up | Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma

27 Jan, 2023 | 11:58h | UTC

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial – Journal of Clinical Oncology

Commentaries:

NIVAHL Trial: Nivolumab and AVD Show Favorable Long-Term Safety and Efficacy in Early-Stage Unfavorable Classical Hodgkin Lymphoma – ASCO Daily News

Concomitant and Sequential Nivolumab, Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of German Hodgkin Study Group NIVAHL Trial – The ASCO Post

Original Study: Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial – JAMA Oncology

 


Review | Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT)

26 Jan, 2023 | 12:46h | UTC

Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT) – Blood

 


2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis

24 Jan, 2023 | 14:29h | UTC

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

Key Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology

News Release: ACC Expert Consensus Decision Pathway Focuses on Diagnosis and Management of Cardiac Amyloidosis – American College of Cardiology

 

Commentary on Twitter

 


ASCO Guideline | Management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients

24 Jan, 2023 | 14:28h | UTC

Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update – Journal of Clinical Oncology

 


RCT | Aspirin noninferior to low-molecular-weight heparin for thromboprophylaxis after a fracture

19 Jan, 2023 | 14:30h | UTC

Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Aspirin as effective as blood thinner injections to prevent deadly complications in patients hospitalized with bone fractures – University of Maryland School of Medicine

Commentary: PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures – TCTMD

 


M-A | Optimal timing of perioperative chemical thromboprophylaxis in elective major abdominal surgery

19 Jan, 2023 | 13:52h | UTC

Optimal Timing of Perioperative Chemical Thromboprophylaxis in Elective Major Abdominal Surgery: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)

 


Review | Management of patients with lower-risk myelodysplastic syndromes

19 Jan, 2023 | 13:47h | UTC

Management of patients with lower-risk myelodysplastic syndromes – Blood Cancer Journal

 


Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

18 Jan, 2023 | 14:37h | UTC

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score – European Heart Journal

See calculator: https://vtepredict.com/

 

Commentary on Twitter

 


Retrospective study | Supernumerary sex chromosome aneuploidies are associated with increased risk of VTE

18 Jan, 2023 | 14:22h | UTC

Association of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism – JAMA (free for a limited period)

 


ESMO Guideline | Venous thromboembolism in cancer patients

15 Jan, 2023 | 20:21h | UTC

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology

Related:

Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

 


Development and validation of a clinical prediction model for the prediction of 5-year survival in Hodgkin Lymphoma

13 Jan, 2023 | 13:12h | UTC

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium – Journal of Clinical Oncology

Commentaries:

HoLISTIC Consortium Develops Reliable Predictive Model for 5-Year Survival in Classic Hodgkin Lymphoma – ASCO Daily News

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma – News Medical

 

Commentary from the author on Twitter (thread – click for more)

 


An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants

13 Jan, 2023 | 13:10h | UTC

News Release: An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants – American Association for Cancer Research

Original Article: Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting – Clinical Cancer Research

Commentary: Study Finds Posoleucel Demonstrated Antiviral Efficacy and Safety Against Viral Infections Following Allogeneic Stem Cell Transplantation – The ASCO Post

 


SR | Laser therapy for retinopathy in sickle cell disease

12 Jan, 2023 | 13:02h | UTC

Laser therapy for retinopathy in sickle cell disease – Cochrane Library

Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library

 


Phase 2 RCT | Upfront autologous HSCT vs. carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in multiple myeloma

12 Jan, 2023 | 12:56h | UTC

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial – The Lancet Haematology

Invited Commentary: Upfront autologous transplantation still improving outcomes in patients with multiple myeloma – The Lancet Haematology

 


Review | Antithrombotic therapy after bioprosthetic aortic valve replacement

12 Jan, 2023 | 12:51h | UTC

How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review – Thrombosis and Haemostasis

 


Review | Platelet transfusion for trauma resuscitation

11 Jan, 2023 | 14:08h | UTC

Platelet Transfusion for Trauma Resuscitation – Current Trauma Reports

 


Special Issue | American Society of Hematology Education Program (series of open-access review articles)

10 Jan, 2023 | 14:26h | UTC

Homepage: American Society of Hematology Education Program – Hematology

 


Chronic lymphocytic leukemia treatment algorithm 2022

10 Jan, 2023 | 14:05h | UTC

Chronic lymphocytic leukemia treatment algorithm 2022 – Blood Cancer Journal

 


Updated Guidance | Acute, periprocedural and long-term antithrombotic therapy in older adults.

16 Dec, 2022 | 13:51h | UTC

Acute, periprocedural and long-term antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis – European Heart Journal

Commentary: Antithrombotic Therapy in Older Adults: Key Points – American College of Cardiology

 


RCT | Zanubrutinib vs. Ibrutinib in relapsed or refractory chronic lymphocytic leukemia.

16 Dec, 2022 | 13:33h | UTC

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Zanubrutinib Found Superior to Ibrutinib for CLL and SLL – The ASCO Post

 


RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.

16 Dec, 2022 | 13:15h | UTC

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial – Gut

 


Major hemorrhage: past, present and future.

13 Dec, 2022 | 14:05h | UTC

Major haemorrhage: past, present and future – Anaesthesia

 


Single-arm P1 study | Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma.

12 Dec, 2022 | 12:38h | UTC

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: More Than 70% of Heavily Pretreated Patients Taking Talquetamab for Multiple Myeloma See Responses That “Deepen Over Time” – AJMC

 

Commentary on Twitter

 


Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.

12 Dec, 2022 | 12:37h | UTC

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.